Hematologic Neoplasms

• 

  Subject Areas on Research

  • A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure. 
  • A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. 
  • A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. 
  • A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. 
  • A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. 
  • Addressing End-of-Life Quality Gaps in Hematologic Cancers: The Importance of Early Concurrent Palliative Care. 
  • Adherence to Measuring What Matters Items When Caring for Patients With Hematologic Malignancies Versus Solid Tumors. 
  • Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. 
  • Advance Care Planning and Palliative Care Specialists in Malignant Hematology and Stem-Cell Transplantation: On Why It Takes A Village. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. 
  • An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. 
  • Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data. 
  • Apoptosis in haematological malignancies. 
  • Applications of Gene Editing Technologies to Cellular Therapies. 
  • B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. 
  • B cells in chronic graft-versus-host disease. 
  • Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. 
  • Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. 
  • Cancer and pregnancy: the clinician's perspective. 
  • Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility? 
  • Carcinogenicity of gasoline: a review of epidemiological evidence. 
  • Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. 
  • Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. 
  • Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies. 
  • Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. 
  • Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. 
  • Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies. 
  • Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. 
  • Coping styles, health status and advance care planning in patients with hematologic malignancies. 
  • Cord-blood engraftment with ex vivo mesenchymal-cell coculture. 
  • Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. 
  • Disparities in place of death for patients with hematological malignancies, 1999 to 2015. 
  • Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers. 
  • Early Palliative Care for Patients with Hematologic Malignancies: Is It Really so Difficult to Achieve? 
  • Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial. 
  • Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. 
  • Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. 
  • Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. 
  • Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India. 
  • Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. 
  • Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. 
  • Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. 
  • Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. 
  • Hemato-oncology and palliative care teams: is it time for an integrated approach to patient care? 
  • Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. 
  • Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. 
  • How I treat refractory chronic graft-versus-host disease. 
  • IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. 
  • Ibrutinib: a new targeted therapy for hematologic cancers. 
  • Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies. 
  • Improving Transitional Care: The Role of Handoffs and Discharge Checklists in Hematologic Malignancies. 
  • Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies. 
  • Individualizing treatment decisions for older adults with hematologic malignancies. 
  • Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. 
  • Information giving and receiving in hematological malignancy consultations. 
  • Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. 
  • Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. 
  • Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. 
  • Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. 
  • Itraconazole and antiretroviral therapy: strategies for empirical dosing - Author's reply. 
  • Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. 
  • Limited Tissue Biopsies and Hematolymphoid Neoplasms. 
  • Linker for activation of T cells (LAT), a novel immunohistochemical marker for T cells, NK cells, mast cells, and megakaryocytes: evaluation in normal and pathological conditions. 
  • Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. 
  • Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases. 
  • Management of adverse events associated with idelalisib treatment: expert panel opinion. 
  • Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. 
  • Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. 
  • Molecular epidemiology of an outbreak of human parainfluenza virus 3 among oncology patients. 
  • Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. 
  • Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment. 
  • Oncology Nurse Navigation: Development and Implementation of a Program at a Comprehensive Cancer Center 
  • One-unit versus two-unit cord-blood transplantation for hematologic cancers. 
  • One-unit versus two-unit cord-blood transplantation. 
  • Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. 
  • Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. 
  • Palliative and End-of-Life Care for Patients With Hematologic Malignancies. 
  • Palliative and End-of-Life Care in Myelodysplastic Syndromes. 
  • Palliative care and hematologic malignancies: old dog, new tricks? 
  • Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. 
  • Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. 
  • Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study. 
  • Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. 
  • Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. 
  • Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. 
  • Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. 
  • Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. 
  • Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. 
  • Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. 
  • Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. 
  • Physician communication styles in initial consultations for hematological cancer. 
  • Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. 
  • Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. 
  • Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. 
  • Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. 
  • Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. 
  • Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. 
  • Prevention of GVHD without losing GVL effect: windows of opportunity. 
  • Quality of life in higher resolution: the next generation of comparative effectiveness research in malignant hematology. 
  • RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. 
  • Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience. 
  • Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. 
  • Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children. 
  • Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. 
  • Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002). 
  • Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. 
  • Reflections on and future of hematologic malignancies research in the Veterans Health Administration. 
  • Regionalization of stem cell transplant procedures into teaching hospitals in United States: are we ready? 
  • Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. 
  • Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. 
  • Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies. 
  • Risk factors for acute GVHD and survival after hematopoietic cell transplantation. 
  • Role of transforming growth factor-beta in hematologic malignancies. 
  • Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors. 
  • Small-molecule nicotinamide for ex vivo expansion of umbilical cord blood. 
  • Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. 
  • Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases. 
  • Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. 
  • Symptom burden of haematological malignancies as death approaches in a community palliative care service: a retrospective cohort study of a consecutive case series. 
  • T-Cell recovery in adults and children following umbilical cord blood transplantation. 
  • Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. 
  • The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review. 
  • The Surprise Question and Identification of Palliative Care Needs among Hospitalized Patients with Advanced Hematologic or Solid Malignancies. 
  • The Use of Indwelling Tunneled Pleural Catheters for Recurrent Pleural Effusions in Patients With Hematologic Malignancies: A Multicenter Study. 
  • The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies. 
  • The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. 
  • The relationship between methylenetetrahydrofolate reductase polymorphism and hematological malignancy. 
  • The role of adenotonsillectomy in graft-versus-host disease. 
  • The vascular niche: home for normal and malignant hematopoietic stem cells. 
  • Thioredoxin and hematologic malignancies. 
  • Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. 
  • Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. 
  • Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. 
  • Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. 
  • Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). 
  • Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. 
  • Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. 
  • Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). 
  • Venous Thromboembolism Risk Assessment and Prophylaxis Use in Pediatric, Adolescent, and Young Adult Hematology Oncology Patients. 
  • Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. 
  • What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a hospice research network. 
  • When and why should patients with hematologic malignancies see a palliative care specialist? 
  • t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? 
• 

  Keywords of People

  • Chen, Jun, Professor of Medicine, Duke Cancer Institute
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Dement, John McCray, Professor Emeritus in Family Medicine and Community Health, Family Medicine & Community Health,Occupational & Environmental Medicine
  • Doan, Phuong Linh, Associate Professor of Medicine, Duke Cancer Institute
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • LeBlanc, Thomas William, Associate Professor of Medicine, Duke Cancer Institute
  • Tsalik, Ephraim, Associate Professor of Medicine, Molecular Genetics and Microbiology